Compare American Superconductor Corporation (AMSC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Superconductor Corporation vs Viatris Inc — how do they compare? American Superconductor Corporation trades at $31.45 (market cap $1.56B), while Viatris Inc trades at $16.1 (market cap $18.49B). The key difference: Viatris Inc is far larger — about 11.9× American Superconductor Corporation's market cap, and Viatris Inc pays a 2.98% dividend while American Superconductor Corporation pays none. Which is the better fit depends on your goals.
| AMSC | VTRS | |
|---|---|---|
Market Cap | $1.56B | $18.49B |
Sector | Technology | Health |
52-Week High | $66.68 | $17.86 |
52-Week Low | $25.95 | $9.49 |
Enterprise Value | $1.42B | $30.61B |
Dividend Yield | — | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMSC trades at $32.28, up 0.47% with bearish technical signals despite strong revenue growth. The company reported record Q1 2026 revenue of $94.1 million, up 30% year-over-year, but missed earnings estimates due to margin pressure. Valuation metrics show a low P/E of 10.48 but elevated EV/EBITDA of 66.03, while analyst consensus leans bullish with 53% buy ratings.
Outlook remains mixed with strong backlog growth ($400M+) supporting visibility, but margin compression and execution risks pose challenges. The stock faces near-term resistance at $33 with support at $32, requiring sustained earnings improvement to justify current valuation levels amid competitive energy tech sector dynamics.
Viatris (VTRS) trades at $16.04, down 1.47% on the day, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.69 exceeding expectations by 14.8%. Recent FDA approval for Gwyn Lo contraceptive patch and divestiture of Tyrvaya nasal spray demonstrate strategic portfolio optimization. Revenue trends show stabilization after declining from $16.3B in 2022 to $14.3B in 2025, with 2026 projections at $14.7B.
While Viatris shows operational strength with consistent cash flow generation and debt reduction, the company faces profitability challenges with negative net income margins and elevated P/E ratio of 236.2. Analyst sentiment is cautiously optimistic with 30.8% buy ratings, though the majority (61.5%) recommend hold. Key risks include ongoing margin pressure, generic drug pricing headwinds, and execution of strategic initiatives amid competitive pharmaceutical landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Superconductor Corporation
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
